Tag: diabetes mellitus

1. Tirzepatide was superior to placebo with regard to changes in HbA1c, serum glucose, body weight loss, and proportion of patients achieving HbA1c targets of less than 7.0%. 2. Compared to placebo, the proportion of adverse events with tirzepatide were mildly elevated. Evidence Rating Level: 1 (Excellent) Study Rundown: In many patients...

1. Time spent cycling was associated with lower all-cause and cardiovascular disease-specific mortality in this multicenter European cohort study of patients with diabetes, independent of other exercise. 2. Taking up cycling over a five-year period was associated with lower mortality rates compared with those who did not cycle at all. Evidence...

1. In patients with type 2 diabetes, use of sodium-glucose cotransporter 2 inhibitors was associated with reduced risk of all-cause mortality compared with sulfonylureas, regardless of cardiovascular disease status, estimated glomerular filtration rate category, and albuminuria status. 2. The addition of SGLT2 inhibitor as a second-line antihyperglycemic agent with metformin...

1. Widespread diabetes screening helps to identify asymptomatic patients with preserved renal function and low diabetes-associated cardiovascular risk. 2. New cardiovascular risk stratification strategies are needed given heterogeneous characteristics of patients with type 2 diabetes.  Evidence Rating Level: 2 (Good)  Study Rundown: In the last decade, New Zealand Ministry of Health has...

1. Matched cohort meta-analysis showed significant morality and life expectancy benefits with metabolic–bariatric surgery compared to non-surgical management of obesity. 2. Survival benefits of bariatric surgery more apparent for individuals with type 2 diabetes.  Evidence Rating Level: 1 (Excellent) Study Rundown: Metabolic syndrome has been associated with significant morbidity and mortality, increasing...

1. Semaglutide 2.4 mg combined with once weekly cagrilintide therapy was not associated with increase in adverse events compared to semaglutide alone. 2. Compared to control, combined cagrilintide and semaglutide improved glycemic parameters and mean body weight reduction at 20 weeks. Evidence Rating Level: 1 (Excellent)  Study Rundown: Semaglutide is a glucagon-like...

1. Hospital readmission and mortality rates were higher in post-COVID patients as compared to matched control groups. 2. More diagnoses of respiratory disease, diabetes, and cardiovascular events were observed in post COVID patients. 3. Older and non-white individuals were at the highest risk for post-COVID complications. Evidence Rating Level: 2 (Good) Study Rundown:...

1. Change in mean bodyweight was -9.6% with semaglutide 2.4 mg vs. -3.4% with placebo. 2. Approximately two-thirds of patients on semaglutide 2.4 mg achieved a target HbA1c of 6.5% or less.  Evidence Rating Level: 1 (Excellent) Study Rundown: There is strong overlap between weight gain and type 2 diabetes, with the...

1. Compared to patients of European descent, poorer health outcomes were seen among Māori and Pacific New Zealanders with type 2 diabetes. 2. Māori patients had the highest incidence rate of all-cause mortality, cardiovascular mortality, and cancer mortality. Evidence Rating Level: 2 (Good) Study Rundown: Disparities associated with ethnicity and socioeconomic status...

1. 10-year remission rates were significantly higher for Roux-en-Y gastric bypass (RYGB) and biliopancreatic diversion (BPD) than medical therapy. 2. Patients in the BPD and RYGB groups had fewer diabetes-related complications.  Evidence Rating Level: 1 (Excellent) Study Rundown: Compared to conventional therapy, metabolic surgery results in significant short-term improvements among patients with...